Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 11, 2009 09:28 ET | Source: Hemispherx Biopharma, Inc.

Hemispherx Biopharma Announces $18.3 Million Public Equity Offerings

PHILADELPHIA, May 11, 2009 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (AMEX:HEB) announced today that it has agreed to sell up to $18.3 million in common stock and warrants in a registered offering to...
April 27, 2009 11:18 ET | Source: Hemispherx Biopharma, Inc.

Japanese Government Accelerates Hemispherx Biopharma's Ampligen(r) Research Programs for Influenza Protection

PHILADELPHIA, April 27, 2009 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE Amex:HEB) announced today that it had received notice of an Annual Report (April 2008- March 2009) prepared by a...
March 17, 2009 14:22 ET | Source: Hemispherx Biopharma, Inc.

Hemispherx Biopharma, Inc. to Discuss New Chronic Fatigue Syndrome Clinical Data and Year-End 2008 Results On March 19, 2009

PHILADELPHIA, March 17, 2009 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE Alternext US:HEB) has scheduled a conference call and audio webcast to discuss its year-end 2008 results and the new...
March 16, 2009 13:50 ET | Source: Hemispherx Biopharma, Inc.

Hemispherx Biopharma, Inc. Announces 2008 Financial Results

PHILADELPHIA, March 16, 2009 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE Alternext US:HEB) announced its financial results for the fiscal year ended December 31, 2008. The net loss for the...
February 18, 2009 13:54 ET | Source: Hemispherx Biopharma, Inc.

Hemispherx Biopharma to Present New Ampligen(r) Clinical Data At the 9th International IACFS/ME Conference

PHILADELPHIA, Feb. 18, 2009 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (AMEX:HEB) announced its medical director, Dr. David Strayer, will present new data on Ampligen(r) (Poly I: Poly C12U) at the...
February 18, 2009 13:42 ET | Source: Hemispherx Biopharma, Inc.

FDA Extends Hemispherx's NDA Review Date for Ampligen(r) as Potential Treatment for CFS

PHILADELPHIA, Feb. 18, 2009 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (AMEX:HEB) has received a letter from the Food and Drug Agency ("FDA") indicating that the originally scheduled Prescription...
January 05, 2009 11:02 ET | Source: Hemispherx Biopharma, Inc.

U.S. Court of Appeals Supports Hemispherx in Rebuff of Hostile Takeover Attempt

PHILADELPHIA, Jan. 5, 2009 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (AMEX:HEB) today announced that its position with respect to alleged illegal manipulation of its stock by foreign business...
December 04, 2008 16:30 ET | Source: Hemispherx Biopharma, Inc.

Hemispherx Biopharma Announces New Chief Financial Officer

PHILADELPHIA, Dec. 4, 2008 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE Alternext US:HEB) announced the appointment of a new Chief Financial Officer (interim), Charles T. Bernhardt, C.P.A,...
November 28, 2008 11:57 ET | Source: Hemispherx Biopharma, Inc.

Attorney Thomas Equels Elected to Hemispherx Biopharma Board of Directors

PHILADELPHIA, Nov. 28, 2008 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (AMEX:HEB), a Philadelphia-based biopharmaceutical company engaged in the manufacture and clinical development of new drug...
November 28, 2008 10:04 ET | Source: Hemispherx Biopharma, Inc.

Hemispherx Biopharma Introduces Expense Reduction Program

PHILADELPHIA, Nov. 28, 2008 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (AMEX:HEB) announced today a series of steps to reduce expenses. As Hemispherx Biopharma continues to strive to...